MCID: THY123
MIFTS: 52

Thyroid Gland Follicular Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Follicular Carcinoma

MalaCards integrated aliases for Thyroid Gland Follicular Carcinoma:

Name: Thyroid Gland Follicular Carcinoma 12
Follicular Thyroid Carcinoma 12 15
Follicular Adenocarcinoma, Well Differentiated 12
Adenocarcinoma, Follicular 44
Follicular Adenocarcinoma 12
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3962
MeSH 44 D018263
NCIt 50 C8054
SNOMED-CT 68 28173006 5257006
UMLS 72 C0206682

Summaries for Thyroid Gland Follicular Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that has material basis in follicular cells.

MalaCards based summary : Thyroid Gland Follicular Carcinoma, also known as follicular thyroid carcinoma, is related to hyperthyroidism and suppurative thyroiditis. An important gene associated with Thyroid Gland Follicular Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Micronutrients and Anti-Infective Agents, Local have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lymph node, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Thyroid Gland Follicular Carcinoma

Diseases related to Thyroid Gland Follicular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 hyperthyroidism 30.7 TSHR TG SST
2 suppurative thyroiditis 30.7 TG CALCA
3 endemic goiter 30.5 TSHR TG
4 ovarian germ cell teratoma 30.4 TG RET NKX2-1
5 thyroiditis 30.3 TSHR TG RET CALCA
6 colloid adenoma 30.3 TG NKX2-1 LGALS3
7 nontoxic goiter 30.2 TSHR TG CALCA
8 parathyroid adenoma 30.1 RET MEN1 CHGA CALCA
9 struma ovarii 30.1 TSHR TG RET NKX2-1
10 congenital hypothyroidism 30.0 TSHR TG PAX8 NKX2-1
11 malignant struma ovarii 30.0 TG RET NKX2-1 LGALS3
12 multiple endocrine neoplasia 30.0 RET MEN1 CHGA CALCA
13 insulinoma 30.0 SST MEN1 CHGA
14 primary hyperparathyroidism 30.0 RET MEN1 CHGA CALCA
15 pituitary tumors 30.0 SSTR5 SST MEN1
16 hyperparathyroidism 29.9 RET MEN1 CHGA CALCA
17 multiple endocrine neoplasia, type i 29.9 SST RET MEN1 CHGA
18 papillary carcinoma 29.9 TSHR TG RET PAX8 NKX2-1 LGALS3
19 meningioma, familial 29.9 SSTR2 SST MEN1
20 papillary thyroid microcarcinoma 29.9 TSHR TG NKX2-1 CALCA
21 nodular goiter 29.9 TSHR TG RET LGALS3 CALCA
22 follicular adenoma 29.9 TSHR TG RET PAX8 NKX2-1 LGALS3
23 multinodular goiter 29.8 TSHR TG PAX8 NKX2-1 CALCA
24 fetal adenoma 29.6 TG NKX2-1 LGALS3 CEACAM5 CALCA
25 hashimoto thyroiditis 29.6 TSHR TG RET LGALS3 CALCA
26 hypothyroidism, congenital, nongoitrous, 2 29.5 TSHR TG PAX8 NKX2-1 LGALS3
27 hypothyroidism 29.5 TSHR TG RET PAX8 NKX2-1 CALCA
28 goiter 29.4 TSHR TG PAX8 NKX2-1 LGALS3 CALCA
29 acromegaly 29.2 SSTR5 SSTR2 SSTR1 SST MEN1
30 adenoma 29.0 TSHR SSTR5 SST RET MEN1
31 differentiated thyroid carcinoma 29.0 TSHR TG RET PPARG PAX8 NKX2-1
32 gastric adenocarcinoma 28.7 SSTR2 CHGA CEACAM5 CCKBR
33 thyroid gland disease 28.7 TSHR TG SST RET PAX8 NKX2-1
34 endocrine gland cancer 28.3 TG SST RET PAX8 MEN1 CHGA
35 thyroid carcinoma, familial medullary 26.1 TG SSTR5 SSTR2 SSTR1 SST RET
36 thyroid cancer, nonmedullary, 2 25.1 TSHR TG SSTR2 SST RET PPARG
37 familial papillary or follicular thyroid carcinoma 12.6
38 trabecular follicular adenocarcinoma 12.4
39 papillary follicular thyroid adenocarcinoma 12.3
40 thyroid carcinoma, hurthle cell 11.7
41 thyroid gland hurthle cell carcinoma 11.5
42 thyroid sarcoma 10.7 TG CALCA
43 wdha syndrome 10.7 SST CALCA
44 water-clear cell adenoma 10.7 TG PAX8
45 duodenal somatostatinoma 10.7 SST CALCA
46 prolactin producing pituitary tumor 10.6 SST CALCA
47 gastrointestinal neuroendocrine benign tumor 10.6 SST CHGA
48 lung oat cell carcinoma 10.6 CHGA CALCA
49 gastric neuroendocrine neoplasm 10.6 SST CHGA
50 type c thymoma 10.6 SSTR2 SST

Graphical network of the top 20 diseases related to Thyroid Gland Follicular Carcinoma:



Diseases related to Thyroid Gland Follicular Carcinoma

Symptoms & Phenotypes for Thyroid Gland Follicular Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Follicular Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 CCKBR LGALS3 NKX2-1 PAX8 PPARG RET
2 homeostasis/metabolism MP:0005376 10.17 CCKBR CHGA LGALS3 MEN1 NKX2-1 PAX8
3 growth/size/body region MP:0005378 10.15 CCKBR CHGA LGALS3 MEN1 NKX2-1 PAX8
4 cardiovascular system MP:0005385 10.11 CCKBR CHGA LGALS3 MEN1 NKX2-1 PAX8
5 endocrine/exocrine gland MP:0005379 10.1 CCKBR CHGA MEN1 NKX2-1 PAX8 PPARG
6 digestive/alimentary MP:0005381 10.03 CCKBR LGALS3 MEN1 NKX2-1 RET SST
7 nervous system MP:0003631 9.97 CCKBR CHGA LGALS3 MEN1 NKX2-1 PAX8
8 neoplasm MP:0002006 9.73 LGALS3 MEN1 NKX2-1 PPARG RET TSHR
9 no phenotypic analysis MP:0003012 9.5 CHGA NKX2-1 PAX8 PPARG RET SST
10 reproductive system MP:0005389 9.23 CHGA LGALS3 MEN1 NKX2-1 PAX8 PPARG

Drugs & Therapeutics for Thyroid Gland Follicular Carcinoma

Drugs for Thyroid Gland Follicular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Micronutrients Phase 2, Phase 3
2 Anti-Infective Agents, Local Phase 2, Phase 3
3 Nutrients Phase 2, Phase 3
4 Trace Elements Phase 2, Phase 3
5 Anti-Infective Agents Phase 2, Phase 3
6
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
7
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
8
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
9
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
10
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
11
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
12
Lenvatinib Approved, Investigational Phase 2 417716-92-8
13
Durvalumab Approved, Investigational Phase 2 1428935-60-7
14
nivolumab Approved Phase 2 946414-94-4
15
Ipilimumab Approved Phase 2 477202-00-9
16
Pembrolizumab Approved Phase 2 1374853-91-4
17
Iodine Approved, Investigational Phase 2 7553-56-2 807
18
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
19
Lenalidomide Approved Phase 2 191732-72-6 216326
20
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
21
Trametinib Approved Phase 2 871700-17-3 11707110
22
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
25
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
26
Tremelimumab Investigational Phase 2 745013-59-6
27
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
28
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
29
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
30 Histone Deacetylase Inhibitors Phase 2
31 Anti-Bacterial Agents Phase 2
32 Antibiotics, Antitubercular Phase 2
33 Antimetabolites, Antineoplastic Phase 2
34 Mitogens Phase 2
35 Fluorides Phase 2
36 Deoxyglucose Phase 2
37 Endothelial Growth Factors Phase 2
38 Antineoplastic Agents, Immunological Phase 2
39 Katacalcin Phase 2
40 calcitonin Phase 2
41 Antibodies, Monoclonal Phase 2
42 cadexomer iodine Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Angiogenesis Modulating Agents Phase 2
45 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
46 Immunologic Factors Phase 2
47 Antibodies Phase 1, Phase 2
48 Immunoglobulins Phase 1, Phase 2
49 Immunoconjugates Phase 1, Phase 2
50 Hormones Phase 1, Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
2 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
3 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
4 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
5 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
6 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
7 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
8 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
9 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
10 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
11 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
12 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
13 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
14 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
15 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib;Cabozantinib S-malate
16 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Recruiting NCT02973997 Phase 2 Lenvatinib
17 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Recruiting NCT02393690 Phase 2 Selumetinib
18 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Recruiting NCT02152995 Phase 2 Trametinib
19 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
20 Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
21 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
22 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
23 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
24 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
25 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
26 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
27 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
28 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
29 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
30 Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. Unknown status NCT01075269
31 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
32 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
33 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
34 Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone Completed NCT01441154
35 Studies on Thyroid Nodules and Thyroid Cancer Recruiting NCT00001160
36 Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions Recruiting NCT00001452
37 Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Active, not recruiting NCT02862470
38 Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples Enrolling by invitation NCT02239575
39 Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study Not yet recruiting NCT03639662

Search NIH Clinical Center for Thyroid Gland Follicular Carcinoma

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Gland Follicular Carcinoma

Anatomical Context for Thyroid Gland Follicular Carcinoma

MalaCards organs/tissues related to Thyroid Gland Follicular Carcinoma:

41
Thyroid, Bone, Lymph Node, Lung, Endothelial, Skin, Brain

Publications for Thyroid Gland Follicular Carcinoma

Articles related to Thyroid Gland Follicular Carcinoma:

(show top 50) (show all 1185)
# Title Authors PMID Year
1
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up. 38
31154561 2019
2
Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule. 38
31211509 2019
3
Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer. 38
31102936 2019
4
Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. 38
31397224 2019
5
DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions. 38
31328658 2019
6
[The analysis of genetic and clinicopathologic characteristics in patients with follicular thyroid neoplasm]. 38
31434450 2019
7
Prediction of follicular thyroid carcinoma associated with distant metastasis in the preoperative and postoperative model. 38
30891875 2019
8
Development and validation of a preoperative prediction model for follicular thyroid carcinoma. 38
31050007 2019
9
IL13RA2 is differentially regulated in Papillary Thyroid Carcinoma versus Follicular Thyroid Carcinoma. 38
31290966 2019
10
Nerve root metastasis of gastric adenocarcinoma: A case report and review of the literature. 38
31302320 2019
11
The surgical dilemma of primary surgery for follicular thyroid neoplasms. 38
31434622 2019
12
An Evaluation of CD61 Immunohistochemistry in Identification of Vascular Invasion in Follicular Thyroid Neoplasms. 38
31218593 2019
13
Modified Transverse-Vertical Gross Examination: a Better Method for the Detection of Definite Capsular Invasion in Encapsulated Follicular-Patterned Thyroid Neoplasms. 38
30661168 2019
14
Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell. 38
30747408 2019
15
Expression and clinicopathological role of miR146a in thyroid follicular carcinoma. 38
30701447 2019
16
Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. 38
31189769 2019
17
Fine-needle aspiration cytology of metastatic spindle cell follicular thyroid carcinoma: A case report. 38
30794342 2019
18
Spectroscopic identification of benign (follicular adenoma) and cancerous lesions (follicular thyroid carcinoma) in thyroid tissues. 38
30954022 2019
19
Follicular Thyroid Carcinoma Presenting as a Manubrium Mass. 38
30973599 2019
20
Ultrasonographic features for differentiating follicular thyroid carcinoma and follicular adenoma. 38
31182260 2019
21
Differences in Mutational Profile between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma Identified Using Next Generation Sequencing. 38
31248021 2019
22
Two distinct E3 ligases, SCFFBXL19 and HECW1, degrade thyroid transcription factor 1 in normal thyroid epithelial and follicular thyroid carcinoma cells, respectively. 38
31238008 2019
23
A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert! 38
31131695 2019
24
Mutation profiles of follicular thyroid tumors by targeted sequencing. 38
31077238 2019
25
In follicular thyroid carcinoma we found, 131I uptake positive bone metastases and negative pulmonary metastases. Whole body 18F-FDG uptake was negative 3 months earlier. 38
31273357 2019
26
Perfluorooctanoic Acid Enhances Invasion of Follicular Thyroid Carcinoma Cells Through NF-κB and Matrix Metalloproteinase-2 Activation. 38
31092435 2019
27
A case of follicular thyroid carcinoma associated with phosphatase and tensin homologue hamartoma tumour syndrome. 38
30575166 2019
28
Cutaneous metastasis from Hürthle cell follicular thyroid carcinoma. 38
30551968 2019
29
Molecular Signature of Prospero Homeobox 1 (PROX1) in Follicular Thyroid Carcinoma Cells. 38
31060342 2019
30
Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. 38
30913992 2019
31
An unsuspicious thyroid nodule with fatal outcome. 38
31140157 2019
32
High-Resolution Raman Microscopic Detection of Follicular Thyroid Cancer Cells with Unsupervised Machine Learning. 38
31035762 2019
33
Papillary thyroid carcinoma presenting as a primary renal tumor with multiple pulmonary and bone metastases: a case report. 38
31003598 2019
34
Role of phospho-ezrin in differentiating thyroid carcinoma. 38
30996241 2019
35
Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR. 38
30682328 2019
36
Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms. 38
30753136 2019
37
Expression of epithelial-mesenchymal transition regulators TWIST, SLUG and SNAIL in follicular thyroid tumours may relate to widely invasive, poorly differentiated and distant metastasis. 38
30368884 2019
38
Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. 38
31027376 2019
39
The diagnostic significance of trophoblast cell-surface antigen-2 expression in benign and malignant thyroid lesions. 38
30971541 2019
40
Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. 38
30747051 2019
41
Differences of HBME-1 Expression in Thyroid Follicular Adenoma and Follicular Thyroid Carcinoma by Ultrasound-Guided Fine-Needle Aspiration Biopsy. 38
30925956 2019
42
Clinicopathologic and Molecular Features of Metastatic Follicular Thyroid Carcinoma in Patients Presenting With a Thyroid Nodule Versus a Distant Metastasis. 38
30557173 2019
43
AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. 38
30851160 2019
44
Pulmonary metastasis of mesonephric-like adenocarcinoma arising from the uterine body: a striking mimic of follicular thyroid carcinoma. 38
30471132 2019
45
Surgical management of follicular thyroid carcinoma in children and adolescents: A study of 30 cases. 38
29935896 2019
46
Genomic Characterization of Differentiated Thyroid Carcinoma. 38
30912334 2019
47
Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference? 38
30673845 2019
48
Posterior Nerve-Sparing Multilevel Cervical Corpectomy and Reconstruction for Metastatic Cervical Spine Tumors: Case Report and Literature Review. 38
30447451 2019
49
MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1. 38
30551451 2019
50
Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy. 38
30536465 2019

Variations for Thyroid Gland Follicular Carcinoma

Cosmic variations for Thyroid Gland Follicular Carcinoma:

9 (show top 50) (show all 271)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM34008 VHL thyroid,NS,carcinoma,follicular carcinoma c.232A>T p.N78Y 3:10142079-10142079 15
2 COSM7340067 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1859C>A p.T620N 14:81143917-81143917 15
3 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 15
4 COSM26449 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1358T>C p.M453T 14:81143416-81143416 15
5 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 15
6 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 15
7 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 15
8 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 15
9 COSM26416 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1867G>T p.A623S 14:81143925-81143925 15
10 COSM6955563 TSC1 thyroid,NS,carcinoma,follicular carcinoma c.257G>T p.R86L 9:132925693-132925693 15
11 COSM7340048 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.10688C>A p.S3563Y 7:99008440-99008440 15
12 COSM7339368 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9227T>C p.I3076T 7:98984957-98984957 15
13 COSM7340052 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.776C>G p.A259G 7:98899743-98899743 15
14 COSM6472133 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.8662C>T p.R2888C 7:98981871-98981871 15
15 COSM20429 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9809G>A p.R3270H 7:98993628-98993628 15
16 COSM7340050 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.4520C>T p.P1507L 7:98948267-98948267 15
17 COSM7339759 TP53BP1 thyroid,NS,carcinoma,follicular carcinoma c.3739C>A p.R1247S 15:43428090-43428090 15
18 COSM10648 TP53 thyroid,NS,carcinoma,follicular carcinoma c.524G>A p.R175H 17:7675088-7675088 15
19 COSM10646 TP53 thyroid,NS,carcinoma,follicular carcinoma c.725G>A p.C242Y 17:7674238-7674238 15
20 COSM11183 TP53 thyroid,NS,carcinoma,follicular carcinoma c.799C>T p.R267W 17:7673821-7673821 15
21 COSM10742 TP53 thyroid,NS,carcinoma,follicular carcinoma c.578A>G p.H193R 17:7674953-7674953 15
22 COSM10656 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 17:7674221-7674221 15
23 COSM10704 TP53 thyroid,NS,carcinoma,follicular carcinoma c.844C>T p.R282W 17:7673776-7673776 15
24 COSM11071 TP53 thyroid,NS,carcinoma,follicular carcinoma c.1009C>T p.R337C 17:7670700-7670700 15
25 COSM43624 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 17:7673745-7673745 15
26 COSM466080 TNKS2 thyroid,NS,carcinoma,follicular carcinoma c.3037A>G p.R1013G 10:91857473-91857473 15
27 COSM7339896 TNKS thyroid,NS,carcinoma,follicular carcinoma c.1969G>C p.A657P 8:9726688-9726688 15
28 COSM7340383 TAF1 thyroid,NS,carcinoma,follicular carcinoma c.587A>T p.E196V 23:71377067-71377067 15
29 COSM377895 STK11 thyroid,NS,carcinoma,follicular carcinoma c.662C>T p.P221L 19:1220645-1220645 15
30 COSM6943090 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.1100T>G p.F367C 23:124051203-124051203 15
31 COSM7340010 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.456C>G p.F152L 23:124042639-124042639 15
32 COSM7339957 SPTA1 thyroid,NS,carcinoma,follicular carcinoma c.2944G>T p.V982F 1:158654703-158654703 15
33 COSM1639597 SPEN thyroid,NS,carcinoma,follicular carcinoma c.3793C>T p.R1265* 1:15930033-15930033 15
34 COSM7340270 SPEN thyroid,NS,carcinoma,follicular carcinoma c.971C>G p.S324* 1:15909410-15909410 15
35 COSM7340015 SNCAIP thyroid,NS,carcinoma,follicular carcinoma c.460C>A p.L154M 5:122423197-122423197 15
36 COSM5880107 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.1060G>C p.V354L 18:51065527-51065527 15
37 COSM5546625 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 18:51058224-51058224 15
38 COSM7339583 SH2B3 thyroid,NS,carcinoma,follicular carcinoma c.640G>A p.G214R 12:111418785-111418785 15
39 COSM7339476 SF3B1 thyroid,NS,carcinoma,follicular carcinoma c.635C>T p.P212L 2:197416772-197416772 15
40 COSM7340173 SETD2 thyroid,NS,carcinoma,follicular carcinoma c.3559G>A p.G1187R 3:47098029-47098029 15
41 COSM7340349 ROS1 thyroid,NS,carcinoma,follicular carcinoma c.578T>C p.V193A 6:117397116-117397116 15
42 COSM7339687 RNF43 thyroid,NS,carcinoma,follicular carcinoma c.1082C>T p.P361L 17:58358694-58358694 15
43 COSM1570338 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 10:43120124-43120124 15
44 COSM4965696 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.1693+1G>A p.? 23:47181867-47181867 15
45 COSM7339411 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2266T>G p.W756G 23:47185541-47185541 15
46 COSM5500823 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2269C>T p.Q757* 23:47185544-47185544 15
47 COSM5546623 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 13:48459766-48459766 15
48 COSM22930 RB1 thyroid,NS,carcinoma,follicular carcinoma c.1510C>T p.Q504* 13:48381258-48381258 15
49 COSM878 RB1 thyroid,NS,carcinoma,follicular carcinoma c.751C>T p.R251* 13:48362847-48362847 15
50 COSM895 RB1 thyroid,NS,carcinoma,follicular carcinoma c.1363C>T p.R455* 13:48379624-48379624 15

Expression for Thyroid Gland Follicular Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Follicular Carcinoma.

Pathways for Thyroid Gland Follicular Carcinoma

GO Terms for Thyroid Gland Follicular Carcinoma

Cellular components related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 TSHR SSTR5 SSTR3 SSTR2 SSTR1 RET

Biological processes related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.87 SSTR5 SSTR3 SSTR2 SSTR1 SST PPARG
2 cell-cell signaling GO:0007267 9.86 TSHR SSTR3 SST CALCA
3 regulation of blood pressure GO:0008217 9.72 PPARG CHGA CALCA
4 cerebellum development GO:0021549 9.71 SSTR3 SSTR2 SSTR1
5 forebrain development GO:0030900 9.71 SSTR3 SSTR2 SSTR1 NKX2-1
6 cellular response to estradiol stimulus GO:0071392 9.69 SSTR3 SSTR2 SSTR1
7 thyroid gland development GO:0030878 9.63 TG PAX8 NKX2-1
8 cellular response to glucocorticoid stimulus GO:0071385 9.61 SSTR5 SSTR3 SSTR2
9 negative regulation of telomerase activity GO:0051974 9.57 PPARG MEN1
10 response to starvation GO:0042594 9.56 SSTR3 SSTR2 SSTR1 PPARG
11 hormone-mediated apoptotic signaling pathway GO:0008628 9.52 SSTR3 SST
12 thyroid-stimulating hormone signaling pathway GO:0038194 9.48 TSHR PAX8
13 neuropeptide signaling pathway GO:0007218 9.46 SSTR5 SSTR3 SSTR2 SSTR1
14 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.35 TSHR SSTR5 SSTR3 SSTR2 SSTR1
15 response to pain GO:0048265 9.27 RET
16 somatostatin signaling pathway GO:0038170 8.92 SSTR5 SSTR3 SSTR2 SSTR1
17 signal transduction GO:0007165 10.15 TSHR TG SSTR5 SSTR3 SSTR2 SSTR1
18 G protein-coupled receptor signaling pathway GO:0007186 10.02 TSHR SSTR5 SSTR3 SSTR2 SSTR1 SST

Molecular functions related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.56 PPARG PAX8 NKX2-1 MEN1
2 hormone activity GO:0005179 9.5 TG SST CALCA
3 neuropeptide binding GO:0042923 9.26 SSTR5 SSTR3 SSTR2 SSTR1
4 thyroid-stimulating hormone receptor activity GO:0004996 9.16 TSHR PAX8
5 somatostatin receptor activity GO:0004994 8.92 SSTR5 SSTR3 SSTR2 SSTR1

Sources for Thyroid Gland Follicular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....